A kit for assisting in judging lymph node metastasis of clinical early endometrial cancer

Abstract

The invention discloses a kit used for assistant determination of clinical early stage endometrial carcinoma lymphonodus metastasis. The kit comprises a parameter acquisition equipment and a readablecarrier; the parameter acquisition equipment comprises an equipment used for acquiring a plurality of parameters relates to the readable carrier; the readable carrier is used for recording following content in formula I: LogitP=-4.992+1.606*G2+2.375*G3+1.383*C+0.871*H+0.869*F, wherein G is used for representing tumor grading value, C is used for representing serum CA125 concentration value, H is used for representing tumor myometrium invasion depth value, F is used for representing cervical stromal involvement degree value, and P is used for representing clinical early stage endometrial carcinoma lymphonodus metastasis risk of human subjects. The kit is used for assistant determination of clinical early stage endometrial carcinoma lymphonodus metastasis risk of human subjects based on clinically easily available tumor differentiation grading, serum CA125 concentration, tumor myometrium invasion depth, and cervical stromal involvement degree.

Description

technical field [0001] The invention relates to a kit for assisting in judging lymph node metastasis of clinical early endometrial cancer, which belongs to the field of biomedicine. Background technique [0002] Endometrial cancer is one of the three most common malignant tumors in women, and its incidence has ranked first among gynecological malignancies in developed countries in Europe and America. With the continuous improvement of living standards in our country, its incidence rate is gradually increasing at a rate of 3.7% per year. In 2015, there were 63,400 new cases of endometrial cancer in my country, and 21,800 people died of endometrial cancer. Patients with endometrial cancer have early symptoms and slow tumor progression. About 83% of them are stage I or stage II when they are first diagnosed. The prognosis of patients with lymph node metastasis is significantly worse, and the 5-year survival rate is only 40%-50%. Therefore, whether lymph node metastasis is an ...

AI Technical Summary

Problems solved by technology

Patients with endometrial cancer have early symptoms and slow tumor progression. About 83% of them are stage I or stage II when they are first diagnosed. The prognosis of patients with lymph node metastasis is significantly worse, and the 5-year survival rate is only 40%-50%

Therefore, whether lymph node metastasis is an important indicator to guide postoperative adjuvant treatment and judge prognosis, but the rate of early lymph node metastasis is low, and it is not clear whether lymph node resection can improve the prognosis of early patients. Lymph node dissection is still controversial. The current guidelines tend to be: for patients with high-risk factors for lymph node metastasis, systematic lymph node resection is required. However, the diagnostic criteria for high-risk lymph node metastasis are not uniform in different countries and medical institutions. The standard of factors is also one of the hotspots in clinical research

Images